Long-Acting Injectable Cabotegravir for HIV Prevention is Safe in Pregnancy
Long-acting injectable cabotegravir (CAB-LA) was safe and well tolerated as HIV pre-exposure prophylaxis (PrEP) before and during pregnancy in a global study among cisgender women, with findings to be presented at the 2024 International AIDS Conference.
Related Clinical Trials
Highlighted Terms
National Institute on Drug AbuseCabotegravirBill & Melinda Gates FoundationEunice Kennedy Shriver National Institute of Child Health and Human DevelopmentHIV Prevention Trials NetworkViiV HealthcareNational Institute of Mental HealthHIVNational Institutes of HealthNCT03164564Gilead Sciences, Inc.National Institute of Allergy and Infectious DiseasesUniversity of the Witwatersrand
Related News
Long-Acting Injectable Cabotegravir for HIV Prevention is Safe in Pregnancy
Long-acting injectable cabotegravir (CAB-LA) was safe and well tolerated as HIV pre-exposure prophylaxis (PrEP) before and during pregnancy in a global study among cisgender women, with findings to be presented at the 2024 International AIDS Conference.